Fluidigm announces pricing of public offering of 8,150,000 shares of common stock

Fluidigm a player in mass cytometry and microfluidics technologies, announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,222,500 shares of common stock at the public offering price.

Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies. The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.